Receptors, Glucocorticoid
"Receptors, Glucocorticoid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example.
| Descriptor ID |
D011965
|
| MeSH Number(s) |
D12.776.826.750.430
|
| Concept/Terms |
Receptors, Glucocorticoid- Receptors, Glucocorticoid
- Receptors, Glucocorticoids
- Glucocorticoids Receptors
- Glucocorticoid Receptors
- Glucocorticoid Receptor
- Receptor, Glucocorticoid
Receptors, Corticoid Type II- Receptors, Corticoid Type II
- Corticoid Type II Receptors
- Corticoid II Receptor
- Receptor, Corticoid II
- Receptors, Corticoid II
- Corticoid II Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Glucocorticoid".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Glucocorticoid".
This graph shows the total number of publications written about "Receptors, Glucocorticoid" by people in this website by year, and whether "Receptors, Glucocorticoid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 4 | 3 | 7 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 5 | 0 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 3 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Glucocorticoid" by people in Profiles.
-
Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors. Cancer Res. 2025 Mar 03; 85(5):875-893.
-
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. Cancer Res Commun. 2024 09 01; 4(9):2415-2426.
-
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760.
-
Study on the mechanism of glucocorticoid receptor mitochondrial translocation and glucocorticoid-induced apoptosis in macrophages. Immunopharmacol Immunotoxicol. 2024 Aug; 46(4):482-495.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543.
-
Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 07; 198(1):137-141.
-
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021 12 06; 12(1):7041.
-
Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. Cell Metab. 2021 08 03; 33(8):1592-1609.e7.
-
A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers. Sci Rep. 2021 05 10; 11(1):9876.